FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190870985> ?p ?o ?g. }

• W3190870985 abstract "Abstract Background Epidermal growth factor receptors (EGFR) are overexpressed on many head and neck squamous cell carcinoma (HNSCC). Radioimmunotherapy (RIT) with F(ab') 2 of the anti-EGFR monoclonal antibody panitumumab labeled with the β-particle emitter, 177 Lu may be a promising treatment for HNSCC. Our aim was to assess the feasibility of a theranostic strategy that combines positron emission tomography (PET) with [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 to image HNSCC and predict the radiation equivalent doses to the tumour and normal organs from RIT with [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 . Results Panitumumab F(ab') 2 were conjugated to DOTA and complexed to 64 Cu or 177 Lu in high radiochemical purity (95.6 ± 2.1% and 96.7 ± 3.5%, respectively) and exhibited high affinity EGFR binding (K d = 2.9 ± 0.7 × 10 − 9 mol/L). Biodistribution (BOD) studies at 6, 24 or 48 h post-injection (p.i.) of [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 (5.5–14.0 MBq; 50 μg) or [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 (6.5 MBq; 50 μg) in NRG mice with s.c. HNSCC patient-derived xenografts (PDX) overall showed no significant differences in tumour uptake but modest differences in normal organ uptake were noted at certain time points. Tumours were imaged by microPET/CT with [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 or microSPECT/CT with [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 but not with irrelevant [ 177 Lu]Lu-DOTA-trastuzumab F(ab') 2 . Tumour uptake at 24 h p.i. of [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 [14.9 ± 1.1% injected dose/gram (%ID/g) and [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 (18.0 ± 0.4%ID/g) were significantly higher ( P < 0.05) than [ 177 Lu]Lu-DOTA-trastuzumab F(ab') 2 (2.6 ± 0.5%ID/g), demonstrating EGFR-mediated tumour uptake. There were no significant differences in the radiation equivalent doses in the tumour and most normal organs estimated for [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 based on the BOD of [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 compared to those estimated directly from the BOD of [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 except for the liver and whole body which were modestly underestimated by [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 . Region-of-interest (ROI) analysis of microPET/CT images provided dose estimates for the tumour and liver that were not significantly different for the two radioimmunoconjugates. Human doses from administration of [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 predicted that a 2 cm diameter HNSCC tumour in a patient would receive 1.1–1.5 mSv/MBq and the whole body dose would be 0.15–0.22 mSv/MBq. Conclusion A PET theranostic strategy combining [ 64 Cu]Cu-DOTA-panitumumab F(ab') 2 to image HNSCC tumours and predict the equivalent radiation doses in the tumour and normal organs from RIT with [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 is feasible. RIT with [ 177 Lu]Lu-DOTA-panitumumab F(ab') 2 may be a promising approach to treatment of HNSCC due to frequent overexpression of EGFR." @default.
• W3190870985 created "2021-08-16" @default.
• W3190870985 creator A5010352217 @default.
• W3190870985 creator A5023465589 @default.
• W3190870985 creator A5042395301 @default.
• W3190870985 creator A5044640197 @default.
• W3190870985 creator A5045343836 @default.
• W3190870985 creator A5058613940 @default.
• W3190870985 creator A5066157385 @default.
• W3190870985 date "2021-08-12" @default.
• W3190870985 modified "2023-10-15" @default.
• W3190870985 title "Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy" @default.
• W3190870985 cites W1967362871 @default.
• W3190870985 cites W1972082925 @default.
• W3190870985 cites W1978830441 @default.
• W3190870985 cites W2000985369 @default.
• W3190870985 cites W2036044644 @default.
• W3190870985 cites W2037401464 @default.
• W3190870985 cites W2039144093 @default.
• W3190870985 cites W2059717684 @default.
• W3190870985 cites W2085219935 @default.
• W3190870985 cites W2085824607 @default.
• W3190870985 cites W2089519905 @default.
• W3190870985 cites W2089663915 @default.
• W3190870985 cites W2112845420 @default.
• W3190870985 cites W2136274526 @default.
• W3190870985 cites W2218133630 @default.
• W3190870985 cites W2275631374 @default.
• W3190870985 cites W2477310414 @default.
• W3190870985 cites W2531150348 @default.
• W3190870985 cites W2607817468 @default.
• W3190870985 cites W2751622614 @default.
• W3190870985 cites W2783479183 @default.
• W3190870985 cites W2789059395 @default.
• W3190870985 cites W2792144047 @default.
• W3190870985 cites W2804272866 @default.
• W3190870985 cites W2889646458 @default.
• W3190870985 cites W2891884133 @default.
• W3190870985 cites W2911146996 @default.
• W3190870985 cites W2997271239 @default.
• W3190870985 cites W2999417355 @default.
• W3190870985 cites W3000668732 @default.
• W3190870985 cites W3009507632 @default.
• W3190870985 cites W3011345420 @default.
• W3190870985 cites W3104946688 @default.
• W3190870985 doi "https://doi.org/10.1186/s41181-021-00140-1" @default.
• W3190870985 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8360260" @default.
• W3190870985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34383182" @default.
• W3190870985 hasPublicationYear "2021" @default.
• W3190870985 type Work @default.
• W3190870985 sameAs 3190870985 @default.
• W3190870985 citedByCount "3" @default.
• W3190870985 countsByYear W31908709852022 @default.
• W3190870985 countsByYear W31908709852023 @default.
• W3190870985 crossrefType "journal-article" @default.
• W3190870985 hasAuthorship W3190870985A5010352217 @default.
• W3190870985 hasAuthorship W3190870985A5023465589 @default.
• W3190870985 hasAuthorship W3190870985A5042395301 @default.
• W3190870985 hasAuthorship W3190870985A5044640197 @default.
• W3190870985 hasAuthorship W3190870985A5045343836 @default.
• W3190870985 hasAuthorship W3190870985A5058613940 @default.
• W3190870985 hasAuthorship W3190870985A5066157385 @default.
• W3190870985 hasBestOaLocation W31908709851 @default.
• W3190870985 hasConcept C126322002 @default.
• W3190870985 hasConcept C159654299 @default.
• W3190870985 hasConcept C170493617 @default.
• W3190870985 hasConcept C178790620 @default.
• W3190870985 hasConcept C185592680 @default.
• W3190870985 hasConcept C197404232 @default.
• W3190870985 hasConcept C202751555 @default.
• W3190870985 hasConcept C203014093 @default.
• W3190870985 hasConcept C2776146153 @default.
• W3190870985 hasConcept C2777807558 @default.
• W3190870985 hasConcept C2778332735 @default.
• W3190870985 hasConcept C2779438470 @default.
• W3190870985 hasConcept C2779931791 @default.
• W3190870985 hasConcept C2779998722 @default.
• W3190870985 hasConcept C2989005 @default.
• W3190870985 hasConcept C502942594 @default.
• W3190870985 hasConcept C542903549 @default.
• W3190870985 hasConcept C55493867 @default.
• W3190870985 hasConcept C71924100 @default.
• W3190870985 hasConceptScore W3190870985C126322002 @default.
• W3190870985 hasConceptScore W3190870985C159654299 @default.
• W3190870985 hasConceptScore W3190870985C170493617 @default.
• W3190870985 hasConceptScore W3190870985C178790620 @default.
• W3190870985 hasConceptScore W3190870985C185592680 @default.
• W3190870985 hasConceptScore W3190870985C197404232 @default.
• W3190870985 hasConceptScore W3190870985C202751555 @default.
• W3190870985 hasConceptScore W3190870985C203014093 @default.
• W3190870985 hasConceptScore W3190870985C2776146153 @default.
• W3190870985 hasConceptScore W3190870985C2777807558 @default.
• W3190870985 hasConceptScore W3190870985C2778332735 @default.
• W3190870985 hasConceptScore W3190870985C2779438470 @default.
• W3190870985 hasConceptScore W3190870985C2779931791 @default.
• W3190870985 hasConceptScore W3190870985C2779998722 @default.
• W3190870985 hasConceptScore W3190870985C2989005 @default.
• W3190870985 hasConceptScore W3190870985C502942594 @default.
• W3190870985 hasConceptScore W3190870985C542903549 @default.
• W3190870985 hasConceptScore W3190870985C55493867 @default.

• next